Taysha Gene Therapies, Inc.

NASDAQ:TSHA

1.42 (USD) • At close November 7, 2024
Bedrijfsnaam Taysha Gene Therapies, Inc.
Symbool TSHA
Munteenheid USD
Prijs 1.42
Beurswaarde 291,019,060
Dividendpercentage 0%
52-weken bereik 1.19 - 4.32
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sean P. Nolan
Website https://www.tayshagtx.com

An error occurred while fetching data.

Over Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment

Vergelijkbare Aandelen

NextCure, Inc. logo

NextCure, Inc.

NXTC

1.32 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.82 USD

Forian Inc. logo

Forian Inc.

FORA

2.03 USD

Leap Therapeutics, Inc. logo

Leap Therapeutics, Inc.

LPTX

3.47 USD

Immuneering Corporation logo

Immuneering Corporation

IMRX

1.93 USD

Precision BioSciences, Inc. logo

Precision BioSciences, Inc.

DTIL

8.42 USD

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

4.32 USD

Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADL

5.09 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)